MDxHealth SA (NASDAQ:MDXH) Receives Average Rating of “Hold” from Brokerages

Shares of MDxHealth SA (NASDAQ:MDXH) have been assigned an average recommendation of “Hold” from the five research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $3.50.

A number of brokerages have recently issued reports on MDXH. William Blair cut shares of MDxHealth from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. BTIG Research lowered their target price on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. Lake Street Capital dropped their price target on shares of MDxHealth from $9.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, May 14th. TD Cowen reiterated a “buy” rating and set a $1.50 price target (down from $7.00) on shares of MDxHealth in a research note on Thursday, May 14th. Finally, Wall Street Zen downgraded MDxHealth from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th.

MDxHealth Stock Down 2.9%

Shares of MDXH opened at $0.41 on Tuesday. The business’s fifty day moving average is $0.56 and its 200 day moving average is $2.11. MDxHealth has a 12-month low of $0.40 and a 12-month high of $5.33. The stock has a market cap of $20.30 million, a P/E ratio of -0.63 and a beta of 1.43.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The business had revenue of $23.90 million for the quarter, compared to analyst estimates of $30.89 million. On average, analysts expect that MDxHealth will post -0.6 EPS for the current year.

Institutional Trading of MDxHealth

Several institutional investors have recently made changes to their positions in MDXH. Bank of America Corp DE raised its holdings in shares of MDxHealth by 213.9% in the first quarter. Bank of America Corp DE now owns 43,492 shares of the company’s stock valued at $100,000 after purchasing an additional 29,638 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in MDxHealth by 21.8% during the first quarter. Renaissance Technologies LLC now owns 304,700 shares of the company’s stock worth $701,000 after purchasing an additional 54,600 shares during the last quarter. Perkins Capital Management Inc. boosted its holdings in MDxHealth by 7.1% during the first quarter. Perkins Capital Management Inc. now owns 1,476,441 shares of the company’s stock worth $3,396,000 after purchasing an additional 97,500 shares during the last quarter. XTX Topco Ltd grew its position in MDxHealth by 220.0% in the 4th quarter. XTX Topco Ltd now owns 40,860 shares of the company’s stock worth $146,000 after purchasing an additional 28,090 shares in the last quarter. Finally, Millennium Management LLC grew its position in MDxHealth by 328.3% in the 4th quarter. Millennium Management LLC now owns 116,831 shares of the company’s stock worth $417,000 after purchasing an additional 89,553 shares in the last quarter.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.